Akeso Inc. has announced a significant label update for its PD-1/VEGF bispecific antibody, ivonescimab, following approval by the National Medical Products Administration in China. The updated label is based on final analysis data from the AK112-301/HARMONi-A Phase III study, which demonstrated statistically significant improvements in both progression-free survival $(PFS)$ and overall survival $(OS)$ for ivonescimab in combination with chemotherapy in patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) that had progressed after EGFR-TKI therapy. The final OS analysis, with a median follow-up of 32.5 months, showed a 26% reduction in the risk of death (OS HR=0.74, P=0.019) and a 54% reduction in the risk of disease progression or death (PFS HR=0.46, P<0.001) compared to chemotherapy alone. No new safety signals were identified. These results have already been presented and led to the approval and inclusion of ivonescimab in China’s National Reimbursement Drug List for both post-EGFR-TKI and first-line PD-L1-positive NSCLC indications.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN58068) on January 07, 2026, and is solely responsible for the information contained therein.
Comments